FN2 Earnings Intelligence
Revvity, Inc. earnings overview
Latest Revvity, Inc. (RVTY) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Revvity, Inc.
Revvity's Q2 supports a constructive operating trajectory: Diagnostics growth, AI-related screening demand and a raised full-year outlook outweighed weakness in Signals software. The evidence is encouraging, but recurring earnings quality depends on backlog conversion and growth without the tariff-refund benefit.
Revvity, Inc.
Revvity's Q1 FY2026 results exceeded consensus, with adjusted EPS of $1.06 versus a $1.02 estimate and revenue of $711.1 million versus $704.1 million, on 3% organic growth and 23.6% adjusted operating margins. The defining strategic move of the quarter is the planned divestiture of the China immunodiagnostics business -- retaining a minority stake with a 2027 closing target -- which management expects to lift pro-forma growth by ~100 bps and margins by ~30 bps. AI-driven software platforms (Xynthetica, BioDesign, LabGistics) are gaining traction with 40% YoY SaaS ARR growth, though a 20% Q2 sequential decline in software revenue is expected. The market responded favorably with a 6.7% move on the report and 9.5% subsequent drift. Management raised full-year guidance.
Revvity, Inc.
Revvity's earnings support a measured version of the growth thesis: resilient diagnostics and life-science demand, AI-enabled software, and disciplined capital allocation provide support, but the maintained outlook and identifiable China, tariff, policy and adoption risks argue against assuming a faster acceleration.
Revvity, Inc.
The quarter provides support for a constructive operating case: software growth, product launches, partnerships, and higher EPS guidance outweighed ongoing China diagnostics pressure. The evidence is positive but does not remove the execution and macro risks identified by management and analysts.
Revvity, Inc.
Revvity’s Q2 results showed resilience through organic growth, a software-led growth area, and cash generation, but the lowered outlook indicates that China reimbursement pressure and broader funding, tariff, and FX risks remain material constraints.
Revvity, Inc.
The supplied analysis offers partial support for a durable-growth case: reagents, software, diagnostics innovation, and partnerships are positive evidence, but instrumentation weakness, FX, and funding or China-related uncertainty remain material constraints.
Revvity, Inc.
The quarter supports a mixed view of Revvity's growth trajectory: diagnostics, reagents, AI-enabled products, and cash generation provide support, but China's instrument weakness and the lower organic-growth outlook temper the near-term case.
Get the RVTY recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.